PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$16.49
0.07 (0.43%)
▲
5d:
-3.45%
30d:
+3.0%
90d:
-19.91%
BUY
HIGH Confidence
Analysis Updated: Apr 29, 2026 12:00 AM ET
Earnings: May 07, 2026
7d
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PHAR appears deeply undervalued. Market expects -46.1% annual earnings decline despite 104% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: PHAR appears deeply undervalued. Market expects -46.1% annual earnings decline despite 104% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.87
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.09
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $16.49, which is considered slightly low relative to its 30-day fair value range of $16.28 to $17.27. From a valuation perspective, the stock is trading at a discount (Forward PE: 44.7) compared to its historical average (285.8). Remarkably, the market is currently pricing in an annual earnings decline of 46.1% over the next few years. This pessimistic expectation contrasts with the company's recent 104.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHAR is in a downtrend. The price is currently testing key support at $16.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.60 (+110.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAR is in a downtrend. The price is currently testing key support at $16.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.60 (+110.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$16.28 -
$17.27
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 110.7% below Wall St target ($34.60)
Trading Range Analysis
30-Day Trading Range
$16.28 -
$17.27
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$16.39
Resistance Level
$17.85
Current Trend
Downtrend
Technical data as of
Apr 29, 2026
Fundamental Context
Forward P/E (Next Year Est.)
44.74
Wall Street Target
$34.60
(+110.7%)
Revenue Growth (YoY)
15.0%
Earnings Growth (YoY)
104.2%
Profit Margin
0.8%
Valuation Discount vs History
-46.1% cheaper
PE vs Historical
44.7 vs 285.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-46.1%
(market-implied from PE analysis)
1-Year Target
$14.78
(-10%)
2-Year Target
$13.30
(-19%)
3-Year Target
$11.97
(-27%)
3-Yr Target (if PE normalizes)
(PE: 45→286)
$76.46
(+366%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 44.7, Growth: 169.3%)
$55.42
(+238%)
Base:
(SPY PE: 20.6, Growth: 169.3%)
$25.53
(+56%)
Bear:
(PE: 17.5, Growth: 169.3%)
$21.70
(+32%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (58x PE), but valuation improves significantly next year (45x PE) as earnings recover.
Forward PE: 58.14 | Forward EPS (Implied): $0.28
Bull Case
$19.83
(+21%)
Analyst growth 15.0%, PE expands to 61.1
Base Case
$16.42
(0%)
Market implied 0.0%, PE stable at 58.1
Bear Case
$12.56
(-24%)
Severe decline -15.0%, PE contracts to 52.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 44.7 to 285.8
Stabilization Target:
$104.89
(+538.8%)
PE Expansion Potential:
+538.8%
Share & Embed Analysis
Last updated: April 29, 2026 3:39 PM ET
Data refreshes hourly during market hours. Next update: 4:39 PM
Data refreshes hourly during market hours. Next update: 4:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 60 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 55 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$878 | 49 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 54 HOLD |
